These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 34481812)

  • 1. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach.
    Chamseddine AN; Assi T; Mir O; Chouaib S
    Pharmacol Ther; 2022 Mar; 231():107986. PubMed ID: 34481812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy.
    Cheruku S; Rao V; Pandey R; Rao Chamallamudi M; Velayutham R; Kumar N
    Int Immunopharmacol; 2023 Mar; 116():109569. PubMed ID: 36773572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
    Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
    J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage targeting in cancer.
    Lopez-Yrigoyen M; Cassetta L; Pollard JW
    Ann N Y Acad Sci; 2021 Sep; 1499(1):18-41. PubMed ID: 32445205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
    Gao J; Liang Y; Wang L
    Front Immunol; 2022; 13():888713. PubMed ID: 35844605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codonopsis pilosula-derived glycopeptide dCP1 promotes the polarization of tumor-associated macrophage from M2-like to M1 phenotype.
    Liu H; Yao M; Ren J
    Cancer Immunol Immunother; 2024 May; 73(7):128. PubMed ID: 38743074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor-associated Macrophage: 
Emerging Targets for Modulating the Tumor Microenvironment].
    Zhou Y; Ren D; Bi H; Yi B; Zhang C; Wang H; Sun J
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):231-240. PubMed ID: 38590197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy drives plasticity and functional polarization of tumor-associated macrophages.
    Kuo WT; Chang JM; Chen CC; Tsao N; Chang CP
    IUBMB Life; 2022 Feb; 74(2):157-169. PubMed ID: 34467634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients.
    Tang J; Ming L; Qin F; Qin Y; Wang D; Huang L; Cao Y; Huang Z; Yin Y
    Immunobiology; 2024 May; 229(3):152805. PubMed ID: 38669865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
    Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
    J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
    Peters S; Paz-Ares L; Herbst RS; Reck M
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor-associated macrophages for cancer immunotherapy.
    Cao X; Lai SWT; Chen S; Wang S; Feng M
    Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
    Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
    Cells; 2022 May; 11(9):. PubMed ID: 35563889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.
    Molgora M; Colonna M
    Med; 2021 Jun; 2(6):666-681. PubMed ID: 34189494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?
    Msaouel P; Genovese G; Gao J; Sen S; Tannir NM
    Expert Opin Ther Targets; 2021 Feb; 25(2):141-151. PubMed ID: 33356674
    [No Abstract]   [Full Text] [Related]  

  • 17. HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization.
    Borowicz S; Principe DR; Dorman MJ; McHenry AJ; Sondarva G; Kumar S; Ananthanarayanan V; Simms PE; Hess A; Rana A
    PLoS One; 2021; 16(6):e0252197. PubMed ID: 34185790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis.
    Chen S; Wang M; Lu T; Liu Y; Hong W; He X; Cheng Y; Liu J; Wei Y; Wei X
    Oncogene; 2023 Sep; 42(37):2737-2750. PubMed ID: 37567973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
    Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
    Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.